Lidocaine patch transdermal - MEDRx

Drug Profile

Lidocaine patch transdermal - MEDRx

Alternative Names: Lidocaine Patch 20% - MEDRx; MRX 5LBT

Latest Information Update: 22 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MEDRx
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Neuropathic pain

Most Recent Events

  • 26 Sep 2016 Pharmacokinetics data from a phase I trial in Neuropathic pain (In volunteers) presented at the World Congress on Pain (WCP-2016)
  • 31 May 2016 MEDRx completes a phase I trial in Neuropathic pain (In volunteers) in Japan
  • 01 May 2016 Phase-I clinical trials in Neuropathic pain (In volunteers) in Japan (Transdermal) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top